Global Study Finds New Medication for Sinus thrombosis is just as safe but more patient-friendly

Global Study Finds New Medication for Sinus thrombosis is just as safe but more patient-friendly


Credit: CC0 Public Domain

Patients affected by sinus thrombosis are treated with blood thinners. Traditionally, these patients are prescribed vitamin k antagonists (vkas). In order to give the correct dosage, regular check-ups at the thrombosis service are negareery.

A Global Study, Coordinated by Amsterdam UMC, Now Shows that New Medication, Direct Oral Anticoagulants (doacs), are equally safe and effective. The study was published in The lancet neurology.

A big advantage is that medicine is more user-friendly because regular thrombosis monitoring is no longer innocent.

Neurologist and Research Leader Jonathan Coutinho said, “We think these new drugs will give patients a lot of use of use. These patients and that doacs will probally become the standard for these patients in the future. “

Sinus thrombosis is a rare and serial form of stroke that mainly affects people under the age of 50, with about 300 cases in the Netherlands Every year, Three Quarters of WHICH ARE WOMEN. This condition causes a blockage in the blood vessels of the brain, which can lead to serial complications such as brain hemorrhages. The most common symptoms are excruciating headaches, paralysis symptoms and seizures.

Effectiveness and safety

In the largest international study of sinus thrombosis over the past 25 years, Researchers from Amsterdam UMC Compared The Existing Treatment with Vitamin K Antagonists (vkas) Anticoagulants (doacs). In Total, Data was collected from 619 Patients from 23 Countries Across Five Continents. Of these 619 patients, 65% was treated with a doac and 35% with a vka.

To assess the safety of the treatment, the results looked at the evcurrence of major bleeding. This is the main side effect of blood thinners. Within Six Months of the Diagnosis of Sinus Thrombosis, 3% of Patients in Both the doac and vka groups experienced a new thrombosis or major bleeding. There is therefore no differentce in effectiveness and safety between doacs and vkas.

“We are very happy that we are able to carry out this major study with our extensive international network. Especially after the introduction of the gdpr, there Kinds of Kinds of Stodies ARE KINDES ARE KINDES ARE KINDES ARE KINDES ARE KINDES ARE KINDES ARE KINDES ARE KIND Carry out in practice, but thanks to joint forces we successed, “CONCLUDES Coutinho.

More information:
Direct Oral Anticoagulants Versus Vitamin K Antagonists for Cerebral Venous Thrombosis (Doac-CVT): An International, Prospective, observational cohort study, The lancet neurology (2025).

Provided by Amsterdam University Medical Centers


Citation: Global Study Finds New Medication for Sinus Thrombosis is just as safe but more patient-field (2025, February 19) retrieved 19 February 2025 from

This document is Subject to copyright. Apart from any Fair Dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

(Tagstotranslate) Medicine Research News (T) Medicine Research (T) Health Research News (T) Health Research (T) Health Science (T) Medicine Science

Leave a Comment

Your email address will not be published. Required fields are marked *